Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy?

Bocanegra Ibarias, Paola y Camacho Ortiz, Adrián y Garza González, Elvira y Flores Treviño, Samantha Maribel y Kim, Hyojin y Pérez Alba, Eduardo (2020) Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? Journal of Global Antimicrobial Resistance, 23. pp. 417-419. ISSN 22137165

Vista previa

Texto 22453.pdf - Versión Publicada Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (514kB) | Vista previa

Resumen

Objectives: We report the successful treatment of a bloodstream infection caused by Klebsiella pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in whom colistin and meropenem therapy had previously failed. Methods: A clinical isolate was evaluated to determine the presence of NDM, TEM, SHV, CTX, and CMY, and the killing kinetics of aztreonam (ATM; 4 mg/mL), aztreonam-avibactam (ATM-AVI; 4/4 mg/mL), and colistin (2 and 4 mg/mL) were tested. Results: ATM-AVI showed in vitro activity against the Klebsiella pneumoniae harbouring NDM-1, whereas colistin allowed re-growth. Conclusions: This report supports reconsideration of use of colistin for treatment of infections caused by K. pneumoniae harbouring NDM. CZA/ATM use should be kept in mind as a treatment option, perhaps earlier than colistin.

Actions (login required)

Ver elemento